These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17085212)

  • 1. Re: Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. I. F. San Francisco, M. M. Regan, W. C. DeWolf and A. F. Olumi, J Urol, 175: 1341-1346, 2006.
    Morales A
    J Urol; 2006 Dec; 176(6 Pt 1):2746; author reply 2746. PubMed ID: 17085212
    [No Abstract]   [Full Text] [Related]  

  • 2. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer.
    San Francisco IF; Regan MM; Dewolf WC; Olumi AF
    J Urol; 2006 Apr; 175(4):1341-5; discussion 1345-6. PubMed ID: 16515994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment total testosterone levels in patients with prostate cancer in the past two decades in Japan.
    Sekine Y; Ito K; Yamamoto T; Nakazato H; Shibata Y; Hatori M; Suzuki K
    Cancer Detect Prev; 2007; 31(2):149-53. PubMed ID: 17418977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
    Stamatiou K; Alevizos A; Mariolis A; Sofras F
    J Urol; 2006 Sep; 176(3):1251-2; author reply 1252. PubMed ID: 16890735
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Prostate cancer in men using testosterone supplementation. F. D. Gaylis, D. W. Lin, J. M. Ignatoff, C. L. Amling, R. F. Tutrone and D. J. Cosgrove.
    Morgentaler A; Rhoden EL; Barqawi AB; Crawford ED
    J Urol; 2006 Apr; 175(4):1572; author reply 1573-4. PubMed ID: 16516047
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
    Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
    Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy.
    Lane BR; Stephenson AJ; Magi-Galluzzi C; Lakin MM; Klein EA
    Urology; 2008 Dec; 72(6):1240-5. PubMed ID: 18692874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur urol 2006;49:54-8.
    Sharma R; Sundar S
    Eur Urol; 2007 Apr; 51(4):1146. PubMed ID: 17161523
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
    Atmaca AF; Balbay MD
    J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. K. Eichler, S. Hempel, J. Wilby, L. Myers, L. M. Bachmann and J. Kleijnen, J Urol, 175: 1605-1612, 2006.
    Eskicorapci SY; Tuncay L
    J Urol; 2006 Dec; 176(6 Pt 1):2745; author reply 2745-6. PubMed ID: 17085209
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
    Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE
    Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Masashi Yano, Takashi Imamoto, Hiroyoshi Suzuki et Al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur urol 2007;51:375-80.
    Morgentaler A
    Eur Urol; 2007 Jul; 52(1):292; author reply 293-4. PubMed ID: 17400361
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Zhao et al.: External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment Score (Urology 2008;72:396-400).
    Stephenson AJ
    Urology; 2008 Sep; 72(3):719-20. PubMed ID: 18762055
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Application of artificial intelligence to the management of urological cancer. M. F. Abbod, J. W. Catto, D. A. Linkens and F. C. Hamdy J Urol 2007; 178: 1150-1156.
    Stephan C; Cammann H; Lein M; Miller K; Jung K
    J Urol; 2008 May; 179(5):2067. PubMed ID: 18355867
    [No Abstract]   [Full Text] [Related]  

  • 16. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
    Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
    Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories: E. A. Klein, F. J. Bianco, A. M. Serio, J. A. Eastham, M. W. Kattan, J. E. Pontes, A. J. Vickers and P. T. Scardino J Urol 2008; 179: 2212-2217.
    Sivanandam A; Bhandari M
    J Urol; 2008 Dec; 180(6):2716-7; author reply 2717-8. PubMed ID: 18951589
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Prostate cancer severity among low income, uninsured men. D. C. Miller, M. S. Litwin, J. Bergman, S. Stepanian, S. E. Connor, L. Kwan and W. J. Aronson. J Urol 2009; 181: 579-584.
    Watson RA
    J Urol; 2010 Mar; 183(3):1259-60; author reply 1260. PubMed ID: 20097378
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. S. E. Eggener, K. A. Roehl, O. Yossepowitch and W. J. Catalona, J Urol 2006; 176: 1399-1403.
    Wagner MD; Daneshmand S; Sokoloff M; Barry JM
    J Urol; 2007 Jun; 177(6):2396; author reply 2396-7. PubMed ID: 17509368
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.